The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / UnitedHealthcare Delays Policy Changes Affecting Physician-Administered Treatments

UnitedHealthcare Delays Policy Changes Affecting Physician-Administered Treatments

October 17, 2019 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On Oct. 1, UnitedHealthcare (UHC) announced updates to its policies for Actemra, Benlysta, Cimzia, Orencia, Simponi Aria and Stelara. The policy changes were effective immediately and required all patients to fail to respond to the self-administered formulation of these drugs prior to obtaining authorization for the physician-administered product. An exception would be granted only if the physician could attest that both the patient and caregiver were unable to administer the drug.

You Might Also Like
  • UnitedHealthcare to Implement Fail-First Requirement for Self-Administered Orencia
  • UnitedHealthCare Rescinds Planned Changes to Orencia Policy
  • UnitedHealthcare Delays Lab Program Implementation in Texas
Also By This Author
  • Volunteers Keep the College Moving Forward

UHC has since delayed the policy changes for Actemra, Benlysta, Cimzia, Orencia and Simponi Aria. Practices should instead refer to the policies that were in effect prior to Oct. 1 for these drugs. The changes to the Stelara policy remain in effect. If a valid prior authorization is in place for office-administered Stelara, it will be honored until its expiration; however, the ACR encourages members to watch these changes closely. UHC has indicated the delayed policies are still under consideration, although no future effective date has been set.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR opposes the requirement to mandate self-administered formulations first and is actively working with other rheumatology groups to advocate for the permanent rescission of the policies.

If you have questions regarding this policy or other insurance coverage concerns, contact practice@rheumatology.org.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Drug Updates, Practice Management Tagged With: Arthritis, prior authorization, UnitedHealthCare (UHC)

You Might Also Like:
  • UnitedHealthcare to Implement Fail-First Requirement for Self-Administered Orencia
  • UnitedHealthCare Rescinds Planned Changes to Orencia Policy
  • UnitedHealthcare Delays Lab Program Implementation in Texas
  • UnitedHealthcare Retires Fax Numbers Used for Prior Authorization Requests

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.